Your time is valuable, so we've drilled down the three most important medtech stories from the past week. But feel free to click the headline to read beyond the blurb.Image by OpenClipart-Vectors on Pixabay
Citing a negative market impact from COVID-19, Alphatec backed out of its agreement to acquire EOS Imaging. While the deal is no longer feasible as contemplated, Alphatec said it is open to a strategic collaboration, if EOS is willing. Earlier this month, Organovo killed a proposed merger with Tarveda Therapeutics, but not because of the pandemic. That decision was prompted by indecisive scientific data on Organovo's part.
Telemedicine is emerging as the hero technology during COVID-19. In the diabetes space, the technology is enabling new patient access to continuous glucose monitoring devices during a time when physician office visits have drastically declined. For companies like Dexcom, this shift is expected to offset some of the impact the company initially saw in new patient opportunities after social distancing measures took effect.
Edwards Lifesciences CEO Mike Mussallem mentioned during the company's first-quarter earnings call that some patients have died because their transcatheter aortic valve replacement (TAVR) procedure was postponed due to COVID-19. The company does, however, expect TAVR procedure volumes to be back to normal by the fourth quarter.